Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010).

被引：0
|
作者：
Ring, Alistair E.
Moretti, Laura
Afshari-Mehr, Angelica
Wardley, Andrew M.
Kilburn, Lucy
Gurel, Bora
MacPherson, Iain R.
Baird, Richard D.
Martin, Sue
Pearson, Alex
Roylance, Rebecca
Winter, Matthew
Dunne, Kathryn
Copson, Ellen
Hickish, Tamas
Stephens, Peter
Burcombe, Russell J.
Randle, Katrina
Bliss, Judith
Turner, Nicholas C.
机构：
[1] Royal Marsden NHS Fdn Trust, Surrey, England
[2] Inst Canc Res, Clin Trials & Stat Unit, London, England
[3] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England
[4] Outreach Res & Innovat Grp, Manchester, England
[5] Inst Canc Res, London, England
[6] Beatson West Scotland Canc Ctr, Glasgow, Scotland
[7] Canc Res UK, Cambridge Ctr, Cambridge, England
[8] Univ Coll London Hosp NHS Fdn Trust, London, England
[9] Univ Coll London Hosp, Biomed Res Ctr, NIHR, London, England
[10] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, England
[11] Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London, England
[12] Univ Southampton, Southampton, England
[13] Royal Bournemouth Hosp, Bournemouth, England
[14] Poole Gen Hosp, Bournemouth, England
[15] Royal Devon & Exeter Hosp, Exeter, England
[16] Maidstone & Tunbridge Wells NHS Trust, Maidstone, Kent, England
[17] Independent Canc Patients Voice, London, England
[18] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1024
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer
    Shafique, Michael
    IsmailKhan, Roohi
    Extermann, Martine
    Sullivan, Dan
    Goodridge, Dawn
    Boulware, David
    Hogue, Deanna
    Soliman, Hatem
    Khong, Hung
    Han, Hyo S.
    ONCOLOGIST, 2019, 24 (07): : 887 - +
  • [42] Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial
    Loap, Pierre
    Loirat, Delphine
    Berger, Frederique
    Ricci, Francesco
    Vincent-Salomon, Anne
    Ezzili, Cyrine
    Mosseri, Veronique
    Fourquet, Alain
    Ezzalfani, Monia
    Kirova, Youlia
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 109 (02): : 436 - 440
  • [43] A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer
    Garrido-Castro, Ana C.
    Graham, Noah
    Bi, Kevin
    Park, Jihye
    Fu, Jingxin
    Keenan, Tanya
    Richardson, Edward Thomas
    Pastorello, Ricardo
    Lange, Paulina
    Attaya, Victoria
    Wesolowski, Robert
    Sinclair, Natalie
    Lucas, Zarah
    Lo, Steve
    Tung, Nadine
    Faggen, Meredith
    Kaufman, Peter A.
    Block, Caroline C.
    Briccetti, Fred
    Toke, Madhavi
    Chen, Wendy
    Wucherpfennig, Kai
    Marx, Sascha
    Agudo, Judith
    Guerriero, Jennifer L.
    Schnitt, Stuart
    Lin, Nancy U.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tayob, Nabihah
    Van Allen, Eliezer
    Tolaney, Sara M.
    CANCER RESEARCH, 2022, 82 (04)
  • [44] The East Carolina Breast Center phase II trial of neoadjuvant metronomic chemotherapy in triple-negative breast cancer
    Raab, R. E.
    Walker, P. R.
    Bellin, L. S.
    Wong, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
    Liu, Jieqiong
    Liu, Qiang
    Li, Ying
    Li, Qian
    Su, Fengxi
    Yao, Herui
    Su, Shicheng
    Wang, Quanren
    Jin, Liang
    Wang, Ying
    Lau, Wan Yee
    Jiang, Zefei
    Song, Erwei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [46] Neoadjuvant phase II trial with carboplatin and eribulin in triple negative breast cancer patients
    Giordano, S. B.
    Jeruss, J. S.
    Bethke, K. P.
    Hansen, N. M.
    Khan, S.
    Von Roenn, J.
    Rosen, S.
    Gradishar, W. L.
    Siziopikou, K. P.
    Meservey, C.
    Kaklamani, V.
    CANCER RESEARCH, 2013, 73
  • [47] Phase II trial of RAD001 plus carboplatin in patients with triple-negative metastatic breast cancer.
    Singh, Jasmeet Chadha
    Stein, Stacy
    Volm, Matthew
    Smith, Julia Anne
    Novik, Yelena
    Speyer, James L.
    Meyers, Marlene
    Adams, Sylvia
    Omene, Coral Oghenerukevwe
    Muggia, Franco
    Schneider, Robert
    Formenti, Silvia
    Davis, Samantha
    Beardslee, Brian
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple-negative breast cancer (mTNBC)
    Obeid, E.
    Miller, K. D.
    Sparano, J. A.
    Blackwell, K.
    Goldstein, L. J.
    CANCER RESEARCH, 2017, 77
  • [49] Phase II trial of selinexor for metastatic triple negative breast cancer
    Han, H. S.
    Ismail-Khan, R.
    Carney, D.
    Extermann, M.
    Hogue, D.
    Soliman, H.
    Loftus, L.
    Lee, J. K.
    Sullivan, D.
    CANCER RESEARCH, 2017, 77
  • [50] A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer
    Joanne L. Blum
    Anthony Gonçalves
    Noa Efrat
    Marc Debled
    Pierfranco Conte
    Paul D. Richards
    Donald Richards
    Pilar Lardelli
    Antonio Nieto
    Martin Cullell-Young
    Suzette Delaloge
    Breast Cancer Research and Treatment, 2016, 155 : 295 - 302
12345